IRIS
VIGNA, ERNESTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.943
NA - Nord America 1.003
EU - Europa 606
SA - Sud America 600
AF - Africa 67
OC - Oceania 2
AN - Antartide 1
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.223
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 923
SG - Singapore 843
BR - Brasile 474
CN - Cina 410
VN - Vietnam 292
IT - Italia 283
HK - Hong Kong 163
DE - Germania 76
KR - Corea 68
FI - Finlandia 53
AR - Argentina 52
GB - Regno Unito 33
MX - Messico 33
CA - Canada 29
UA - Ucraina 26
BD - Bangladesh 24
NL - Olanda 24
ZA - Sudafrica 23
FR - Francia 22
RU - Federazione Russa 22
AT - Austria 21
IQ - Iraq 20
EC - Ecuador 19
PK - Pakistan 19
ID - Indonesia 15
IN - India 15
CO - Colombia 14
PY - Paraguay 12
JP - Giappone 10
UY - Uruguay 8
CL - Cile 7
DZ - Algeria 7
EG - Egitto 7
JO - Giordania 7
KE - Kenya 7
PL - Polonia 7
UZ - Uzbekistan 7
MA - Marocco 6
ET - Etiopia 5
IL - Israele 5
PA - Panama 5
PE - Perù 5
TR - Turchia 5
VE - Venezuela 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
KG - Kirghizistan 4
PH - Filippine 4
AL - Albania 3
BA - Bosnia-Erzegovina 3
BG - Bulgaria 3
BO - Bolivia 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
KZ - Kazakistan 3
LB - Libano 3
RO - Romania 3
SA - Arabia Saudita 3
SE - Svezia 3
TN - Tunisia 3
CH - Svizzera 2
DK - Danimarca 2
ES - Italia 2
GT - Guatemala 2
KH - Cambogia 2
LT - Lituania 2
MK - Macedonia 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AQ - Antartide 1
BN - Brunei Darussalam 1
BS - Bahamas 1
BW - Botswana 1
CG - Congo 1
CW - ???statistics.table.value.countryCode.CW??? 1
GA - Gabon 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
IE - Irlanda 1
JM - Giamaica 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
LY - Libia 1
ME - Montenegro 1
MO - Macao, regione amministrativa speciale della Cina 1
NZ - Nuova Zelanda 1
PF - Polinesia Francese 1
PS - Palestinian Territory 1
PT - Portogallo 1
QA - Qatar 1
Totale 4.221
Salva come PNG Salva come JPEG
Città #
Singapore 333
Dallas 226
Hong Kong 161
Boardman 138
Florence 136
Ho Chi Minh City 110
Hefei 107
Ashburn 103
Beijing 84
Seoul 68
Hanoi 60
São Paulo 48
Shanghai 45
Munich 41
Helsinki 37
Los Angeles 30
Sesto Fiorentino 22
Noto 20
Rio de Janeiro 19
New York 18
Milan 17
Santa Clara 17
The Dalles 14
Brooklyn 13
Guangzhou 13
Montreal 13
Vienna 13
Washington 12
Brasília 11
Da Nang 11
Haiphong 11
Johannesburg 10
Mexico City 10
Quito 10
Tokyo 10
Biên Hòa 9
Rome 9
Turku 9
Wuhan 9
Amsterdam 8
Baghdad 8
Belo Horizonte 8
Ninh Bình 8
Phoenix 8
Amman 7
Catania 7
Guayaquil 7
Lappeenranta 7
London 7
Montevideo 7
Naaldwijk 7
Ogden 7
Ribeirão Preto 7
San Francisco 7
Thái Nguyên 7
Atlanta 6
Boston 6
Cape Town 6
Chicago 6
Fortaleza 6
Karachi 6
Medellín 6
Nairobi 6
Santo André 6
Tashkent 6
Addis Ababa 5
Campinas 5
Dhaka 5
Elk Grove Village 5
Kyiv 5
Maceió 5
Nuremberg 5
Bắc Giang 4
Cairo 4
Chandler 4
Charlotte 4
Council Bluffs 4
Denver 4
Feira de Santana 4
Formosa 4
Frankfurt am Main 4
Goiânia 4
Hải Dương 4
La Plata 4
Quảng Ngãi 4
Recife 4
Salvador 4
Thái Bình 4
Toronto 4
Vinh 4
Americana 3
Baku 3
Bishkek 3
Blumenau 3
Bogotá 3
Brescia 3
Can Tho 3
Caxias do Sul 3
Chapecó 3
Ciudad del Este 3
Totale 2.341
Salva come PNG Salva come JPEG
Nome #
Bruton Tyrosine Kinase Inhibitors in Mantle Cell Lymphoma: What Are the Current Options? 142
Efficacy of eculizumab in severe ADAMTS13-deficient thrombotic thrombocytopenic purpura (TTP) refractory to standard therapies 95
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients 90
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials 89
Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol 89
Momelotinib in myelofibrosis 86
Lymphocyte Doubling Time As A Key Prognostic Factor To Predict Time To First Treatment In Early-Stage Chronic Lymphocytic Leukemia 84
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials 80
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 79
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 79
Elotuzumab in multiple myeloma 77
Comparison of isatuximab-pomalidomide-dexamethasone versus elotuzumab-pomalidomidedexamethasone in relapsed/refractory multiple myeloma patients: a target trial emulation using real-world data 76
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective real-world experience with 200 cases outside of controlled clinical trials 76
Belantamab mafodotin in multiple myeloma 76
Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study 75
Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia Successfully Treated with Rituximab-Venetoclax: A Case Report 75
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 74
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 72
Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma 72
Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives 71
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 71
Vaccination in Multiple Myeloma: Challenges and Strategies 70
Cerebral pheohyphomycosis due to curvularia species 69
Mechanisms of Immune Evasion in Multiple Myeloma: Open Questions and Therapeutic Opportunities 67
Acalabrutinib in chronic lymphocytic leukemia 67
Selinexor in multiple myeloma 66
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials 65
Ivosidenib in acute myeloid leukemia 64
Iron chelation therapy 64
MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study 63
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials 62
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab‐, Elotuzumab‐, and Carfilzomib‐Based Triplet Regimens: A Multicenter Real‐World Analysis of 635 Patients 60
Teclistamab-cqyv in multiple myeloma 60
Myelodysplastic syndromes with ring sideroblasts 59
TP53‐Mutated Acute Myeloid Leukemia: Unanswered Questions 58
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real‐life multicenter Italian cohort 58
The role of corticosteroids in the current treatment paradigm for myelofibrosis 57
Comparison of two scores in predicting pulmonary embolism-related adverse events in intermediate-high-risk patients: a systematic review and meta-analysis 57
Frailty predicts treatment-related toxicity and discontinuation in older adults with chronic lymphocytic leukemia treated with BTK and BCL-2 inhibitors: Findings from a prospective single-center cohort study 56
Isatuximab, pomalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: the Italian, multicenter, retrospective clinical experience with 270 cases outside of controlled clinical trials 56
Therapeutic Strategies for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients: Optimizing the Use of Monoclonal Antibodies 55
Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients 53
Anti-CD38 monoclonal antibodies in multiple myeloma with gain/amplification of chromosome arm 1q: a review of the literature 53
Avatrombopag for the Treatment of Immune Thrombocytopenia 52
Advances and Challenges in Quizartinib‐Based FLT3 Inhibition for Acute Myeloid Leukemia: Mechanisms of Resistance and Prospective Combination Therapies 52
Multisystem Inflammatory Syndrome after Ad26.COV2.S vaccination 51
Rilzabrutinib for the Treatment of Immune Thrombocytopenia 51
Zanubrutinib for the treatment of chronic lymphocytic leukemia 51
Safety and efficacy of caplacizumab in a case of thrombotic thrombocytopenic purpura in the postpartum period 50
Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report 50
Maintenance therapy after ASCT in newly diagnosed multiple myeloma patients: single agent versus combination drugs 50
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study 49
Glasdegib for the treatment of acute myeloid leukemia 49
Therapy‐Related Acute Promyelocytic Leukemia: Case Series and Current Insights 48
Myelodysplastic syndromes del(5q): Pathogenesis and its therapeutic implications 46
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients 46
Tagraxofusp in myeloid malignancies 46
Potential of BGB-1417, a BCL2 inhibitor, in hematological malignancies 44
Treatment-Free Remission in Chronic Myeloid Leukemia: Revisiting the "W" Questions 44
Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions 43
Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura 42
Isatuximab in multiple myeloma 42
Mosunetuzumab for the treatment of follicular lymphoma 42
Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens 41
Performance of the Bova score in predicting short-term all-cause mortality in patients with pulmonary embolism and normal blood pressure. A systematic review and meta-analysis 38
Venetoclax in acute myeloid leukemia 38
Investigational CXCR4 inhibitors in early phase development for the treatment of hematological malignancies 36
The potential of triplet combination therapies for patients with FLT3-ITD -mutated acute myeloid leukemia 28
Clinical Utility of Frailty Scoring in Elderly Acute Myeloid Leukemia Patients Treated With Venetoclax and Hypomethylating Agents 23
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 19
Real‐World Evaluation of Oral Decitabine/Cedazuridine in Elderly Patients With Acute Myeloid Leukemia 17
Herpes Zoster in Hematological Disorders: Pathogenesis, Risk Stratification, and Emerging Strategies for Prevention and Immunization 17
T‐Cell–Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions 16
Extracellular vesicles in multiple myeloma-bone marrow niche crosstalk: from cellular dialogue to clinical perspectives 13
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies 6
Totale 4.307
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212 0 0 0 0 0 0 0 1 0 1 0 0
2021/20228 0 2 0 0 2 0 0 1 0 0 1 2
2022/202376 2 0 0 2 1 1 32 3 4 5 20 6
2023/2024536 10 17 105 85 49 64 24 18 17 9 19 119
2024/20251.273 48 104 33 65 62 47 24 64 197 131 134 364
2025/20262.406 451 252 423 333 736 211 0 0 0 0 0 0
Totale 4.307